Therapy resistance on the RADar in ovarian cancer.

Schwickert, Jonas; Zickgraf, Franziska M; Sprick, Martin R

Schwickert, Jonas; Zickgraf, Franziska M; Sprick, Martin R.

Afiliação

Schwickert J; Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Zickgraf FM; Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), Heidelberg, Germany.
Sprick MR; Faculty of Biosciences, Heidelberg University, Heidelberg, Germany.

EMBO Mol Med ; 13(5): e14010, 2021 05 07.

Article em En | MEDLINE | ID: mdl-33779077

ABSTRACT

ABSTRACT

Ovarian cancer has the worst prognosis of all gynecological cancers with high-grade serous ovarian cancer (HGSOC) accounting for the majority of ovarian cancer deaths. Therapy resistance and the selection of effective therapies for patients remains a major challenge. In this issue of EMBO Molecular Medicine, Hoppe et al present RAD51 expression as a biomarker of platinum resistance in high-grade serous ovarian cancer (HGSOC) patients (Hoppe et al, 2021).

Assuntos

Neoplasias Ovarianas; Radar; Carcinoma Epitelial do Ovário; Feminino; Humanos; Neoplasias Ovarianas/tratamento farmacológico

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Radar Limite: Female / Humans Idioma: En Revista: EMBO Mol Med Assunto da revista: BIOLOGIA MOLECULAR Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Alemanha

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google